Accelerated Phase Chronic Myelogenous Leukemia Completed Phase 2 Trials for Cyclophosphamide (DB00531)

IndicationStatusPhase
DBCOND0028985 (Accelerated Phase Chronic Myelogenous Leukemia)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01175785Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic MalignanciesTreatment
NCT01427881Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological MalignanciesTreatment
NCT00049504Fludarabine Phosphate, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Total-Body Irradiation, and Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancerTreatment
NCT01177371High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaTreatment